487 related articles for article (PubMed ID: 33308041)
1. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
[TBL] [Abstract][Full Text] [Related]
2. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract][Full Text] [Related]
3. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
Chen X; Wu X; Wu H; Gu Y; Shao Y; Shao Q; Zhu F; Li X; Qian X; Hu J; Zhao F; Mao W; Sun J; Wang J; Han G; Li C; Xia Y; Seesaha PK; Zhu D; Li H; Zhang J; Wang G; Wang X; Li X; Shu Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33172881
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
6. Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
Bishnoi S; Kotasek D; Aghmesheh M; Yau T; Cosman R; Prawira A; Moore M; Chan SL; Mant A; Eek R; Zielinski R; Su R; Pan Z; Ma Y; Li F; Li P; Tse AN
Cancer; 2024 Jun; 130(11):1991-2002. PubMed ID: 38404184
[TBL] [Abstract][Full Text] [Related]
7. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
8. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial.
Chen X; Qin S; Gu S; Ren Z; Chen Z; Xiong J; Liu Y; Meng Z; Zhang X; Wang L; Zhang X; Zou J
Int J Cancer; 2021 Dec; 149(11):1944-1954. PubMed ID: 34309846
[TBL] [Abstract][Full Text] [Related]
9. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
Arkenau HT; Martin-Liberal J; Calvo E; Penel N; Krebs MG; Herbst RS; Walgren RA; Widau RC; Mi G; Jin J; Ferry D; Chau I
Oncologist; 2018 Dec; 23(12):1407-e136. PubMed ID: 29853658
[TBL] [Abstract][Full Text] [Related]
11. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
Xie L; Xu J; Sun X; Guo W; Gu J; Liu K; Zheng B; Ren T; Huang Y; Tang X; Yan T; Yang R; Sun K; Shen D; Li Y
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376724
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
13. Blood tests predict the therapeutic prognosis of anti-PD-1 in advanced biliary tract cancer.
Du F; Qiu Z; Ai W; Huang C; Ji J; Xiao X; Zhou J; Fang M; Jiang X; Gao C
J Leukoc Biol; 2021 Aug; 110(2):327-334. PubMed ID: 33724548
[TBL] [Abstract][Full Text] [Related]
14. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.
Lv JW; Li JY; Luo LN; Wang ZX; Chen YP
J Immunother Cancer; 2019 Jun; 7(1):159. PubMed ID: 31238988
[TBL] [Abstract][Full Text] [Related]
15. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW
JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498
[TBL] [Abstract][Full Text] [Related]
17. The clinical application of camrelizumab on advanced hepatocellular carcinoma.
Chen Z; Lu X; Koral K
Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1017-1024. PubMed ID: 32762583
[TBL] [Abstract][Full Text] [Related]
18. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E
J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
Piha-Paul SA; Oh DY; Ueno M; Malka D; Chung HC; Nagrial A; Kelley RK; Ros W; Italiano A; Nakagawa K; Rugo HS; de Braud F; Varga AI; Hansen A; Wang H; Krishnan S; Norwood KG; Doi T
Int J Cancer; 2020 Oct; 147(8):2190-2198. PubMed ID: 32359091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]